FDA approves CSL's Haegarda for HAE

FDA approved Haegarda (subcutaneous C1-INH, CSL830) from CSL Ltd. (ASX:CSL) to prevent hereditary angioedema (HAE) in adolescent and adult patients. The agency said Haegarda, which has Orphan Drug st...